Molecular NeuroImaging, LLC (MNI) has experience and operational knowledge of brain imaging using SPECT and PET modalities to support clients throughout the drug development and clinical research for neurodegenerative and neuropsychiatric disorders process.
MNI has developed a unique, vertically-integrated business operation providing services across the preclinical and clinical spectrum including:
- Radioligand development, production, distribution
- Assessment in preclinical models
- Design and implementation of Phase 1 to Phase 4 clinical imaging trials
- Customized worldwide clinical imaging site coordination and management in multi-site imaging studies.